Texture Analysis Now Included in VIDA InsightsTM

COVID-19 & ILD Challenges

COVID-19 Predicting progression and mortality risk to inform treatment decisions - when to be aggressive with therapy?

COVID-19 Understanding comorbidity to get a complete patient picture - patients with COPD have a 5.9 fold higher risk of COVID progression.1

COVID-19 Understanding complications and long lasting effects in recovering patients - who is at risk of readmission and why is recovery stalling?

ILD Identifying ILD patients early - 73% of patients have an 1+ year diagnostic delay.2

ILD

Getting an accurate ILD diagnosis - 55% of patients are initially misdiagnosed.3

ILD Assessing progression objectively - Subjective measures of progression may limit care decisions.   

  

Availability
VIDA Insights is clinically cleared in the US, EU, Australia & Canada. Texture and Subpleura View are available in the US and Canada under the public health emergency and available for research use in the EU and Australia. 

VIDA's Texture Analysis empowers physicians to address these challenges

Texture Quantification

VIDA Insights provides quantitative measures and distribution of ground glass/reticulation, consolidation and honeycombing.

An overlay of these findings is also provided together with hyperlucent tissue, indicative of emphysema.

COVID-19 Published works are indicating a primary imaging feature of COVID-19 to include ground-glass opacities with or without consolidation.4,5 

COVID-19 Quantitative lung consolidation is associated with the occurrence of major adverse hospital events for COVID-19 patients.6 

ILDHCRT features frequently seen in UIP (usual interstitial pneumonia) include reticulation, honeycombing and may be seen with the concurrent presence of ground-glass opacifications.7

UIP may or may not include the presence of traction bronchiectasis and/or traction bronchiolectasis which can be quickly identified with VIDA’s tMPR views. 
texture-analysis-1

Texture Analysis, COVID-19 Case

Download

Texture Visualization

COVID-19   ILD  Subpleura View provides an impactful visualization of the 1mm space below the pleura, to quickly identify the presence or absence of textures in this space. This is especially useful in ILD and COVID-19 cases where these diseases often manifest. 

Subpleura View is our latest visualization innovation, joining tMPR (topographic MPR) and others to give providers a modern way to see key imaging features. Subpleura View is patent pending.  

rotation-subpleura view

Subpleura View, COVID-19 Case

IPF sub-pleural

Subpleura View with Honeycombing

 Comorbid Assessment

All Diseases  VIDA Insights also provides density analysis and tMPR visualizations, assisting providers with:

  • Opportunistic screening of diseases associated with low attenuation (emphysema) or high attenuation (ILAs).  These quick flags of clinically significant findings aim to improve the dismal late-diagnose statistics associated with both COPD and ILD.5,8    
  • Immediate global impression of the patient with tMPR, resulting in increased efficiency, often making the subtle finding obvious.   
  • Quantitative results, empowering precision healthcare.
"VIDA Insights reduces the stress of the read.  I feel like someone is reviewing the case with me."
newell-2

John Newell, MD, FACR
Radiologist

MicrosoftTeams-image (1)-1

Density Analysis, COVID-19 Case

tMPR Visualizations, UIP Case

VIDA Insights is clinically cleared in the US, EU, Australia & Canada. Texture and Subpleura View are available in the US and Canada under the public health emergency and available for research use in the EU and Australia. 

References

1. Wang, Bolin, Ruobao Li, Zhong Lu, and Yan Huang. “Does Comorbidity Increase the Risk of Patients with COVID-19: Evidence from Meta-Analysis.” Aging 12 (April 8, 2020). https://doi.org/10.18632/aging.103000.
2. Rahman, K. K. Mujeeb, and J. K. Samaria. “Diagnostic Delay and Misdiagnosis in Interstitial Lung Disease(ILD) at Primary Health Care Level.” European Respiratory Journal 48, no. suppl 60 (September 1, 2016). https://doi.org/10.1183/13993003.congress-2016.PA861.
3. Cosgrove, Gregory P., Pauline Bianchi, Sherry Danese, and David J. Lederer. “Barriers to Timely Diagnosis of Interstitial Lung Disease in the Real World: The INTENSITY Survey.” BMC Pulmonary Medicine 18 (January 17, 2018). https://doi.org/10.1186/s12890-017-0560-x.
4. Colombi et al “Well-Aerated Lung on Admitting Chest CT to Predict Adverse Outcome in COVID-19 Pneumonia.” Radiology, April 17, 2020, 201433. https://doi.org/10.1148/radiol.2020201433.
5. Wang, Bolin, et al. “Does Comorbidity Increase the Risk of Patients with COVID-19: Evidence from Meta- Analysis.” Aging, vol. 12, Apr. 2020. PubMed, doi:10.18632/aging.103000 
6. Sapienza, Lucas G., Karim Nasra, Vinícius F. Calsavara, Tania B. Little, Vrinda Narayana, and Eyad Abu-Isa. “Risk of In-Hospital Death Associated with Covid-19 Lung Consolidations on Chest Computed Tomography – A Novel Translational Approach Using a Radiation Oncology Contour Software.” European Journal of Radiology Open 8 (January 1, 2021): 100322. https://doi.org/10.1016/j.ejro.2021.100322. 
7. Raghu, Ganesh, Martine Remy-Jardin, Jeffrey L. Myers, Luca Richeldi, Christopher J. Ryerson, David J. Lederer, Juergen Behr, et al. “Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.” American Journal of Respiratory and Critical Care Medicine 198, no. 5 (September 2018): e44–68. https://doi.org/10.1164/rccm.201807-1255ST.
8. Mapel, Douglas W, Anand A Dalal, Christopher M Blanchette, Hans Petersen, and Gary T Ferguson. “Severity of COPD at Initial Spirometry-Confirmed Diagnosis: Data from Medical Charts and Administrative Claims.” International Journal of Chronic Obstructive Pulmonary Disease 6 (2011): 573–81. https://doi.org/10.2147/COPD.S16975.

Additional Resources

webinar
youtube
forbes
aimed-1

AIMed Interview:
AI and the COVID-19 Pandemic